Last reviewed · How we verify
BBI608
BBI608 is a Wnt/β-catenin pathway inhibitor that targets cancer stem cells by blocking their self-renewal capacity.
BBI608 is a Wnt/β-catenin pathway inhibitor that targets cancer stem cells by blocking their self-renewal capacity. Used for Colorectal cancer (in combination with chemotherapy), Pancreatic cancer (in combination with chemotherapy), Gastric cancer (in combination with chemotherapy).
At a glance
| Generic name | BBI608 |
|---|---|
| Also known as | Napabucasin, BB608, BBI-608 |
| Sponsor | NCIC Clinical Trials Group |
| Drug class | Wnt/β-catenin pathway inhibitor |
| Target | β-catenin / Wnt signaling pathway |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
BBI608 inhibits the Wnt signaling pathway, which is critical for cancer stem cell maintenance and tumor growth. By disrupting β-catenin-mediated transcription, the drug aims to eliminate the population of cancer stem cells responsible for tumor initiation, progression, and chemotherapy resistance. This mechanism is intended to work synergistically with conventional chemotherapy agents.
Approved indications
- Colorectal cancer (in combination with chemotherapy)
- Pancreatic cancer (in combination with chemotherapy)
- Gastric cancer (in combination with chemotherapy)
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Fatigue
- Abdominal pain
Key clinical trials
- A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer (PHASE1)
- A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies (PHASE1, PHASE2)
- A Study of BBI608 in Combination With Temozolomide in Adult Patients With Recurrent or Progressed Glioblastoma (PHASE1, PHASE2)
- A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer (PHASE2)
- A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer (PHASE3)
- A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma (PHASE3)
- A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer (PHASE3)
- A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BBI608 CI brief — competitive landscape report
- BBI608 updates RSS · CI watch RSS
- NCIC Clinical Trials Group portfolio CI